Skip to main content
. Author manuscript; available in PMC: 2015 May 4.
Published in final edited form as: Cancer Immunol Res. 2014 Feb 3;2(5):399–403. doi: 10.1158/2326-6066.CIR-13-0193

Figure 1.

Figure 1

PSA trend for patient. Day 0 is the first treatment with ipilimumab. Day 21 is the second treatment. Day 42 is the half-dose third treatment after which no subsequent doses were given. PSA remained undetectable for 16 months, and once hormone suppression was withdrawn, became detectable at low levels compatible with an intact prostate gland and has remained stable for 5 years since the initiation of therapy.